Document is current
Any future updates will be listed below
-
Authors
Möhwald, Lukas Maximilian https://orcid.org/0009-0007-3401-2324
Maier, André
Grehl, Torsten
Weyen, Ute
Weydt, Patrick
Günther, René
Lingor, Paul
Göricke, Bettina
Petri, Susanne
Grosskreutz, Julian
Boentert, Matthias
Cordts, Isabell
Weishaupt, Jochen H.
Dorst, Johannes
Münch, Christoph
Meyer, Thomas
Baum, Petra
-
Funding
Funding for this research was provided by:
Open Access Publishing Fund of Leipzig University (Open Access Publishing Fund of Leipzig University (“Read & Publish” contract with Springer Nature))
- License Information
-
More Information
Article History
Received: 19 October 2024
Accepted: 9 December 2024
First Online: 6 February 2025
Declarations
:
: This study complies with the Declaration of Helsinki. Approval for this study was obtained from the Medical Ethics Committee of Charité - Universitätsmedizin Berlin, Germany, under the number EA2/168/20. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: TM is on the advisory board of Biogen and has received consulting fees from Biogen. TM and CM are founders and shareholders of Ambulanzpartner Soziotechnologie APST GmbH, which developed the internet platform Ambulanzpartner and the mobile application “ALS-App.” APST has received a research grant from Biogen. PL has received grants from the Federal Ministry of Education and Research (BMBF) and the German Research Foundation (DFG), consulting fees from AbbVie, Amylyx, Bial, Desitin, ITF Pharma, Novartis, Stadapharm, Raya Therapeutic, Woolsey Pharmaceuticals, and Zambon outside of the submitted work, as well as support for attending meetings and travel from AbbVie. He is co-inventor on patents EP 2825175 B1, US 9.980,972 B2 for the use of Fasudil in ALS and has participated on an advisory board for Novartis and Trace Neuroscience. The other authors declare that they have no conflicts of interest related to the material discussed in the manuscript.
